NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Thursday, February, 6th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.59 by $0.06. The biotechnology company had revenue of $52.57 million for the quarter, compared to analysts' expectations of $58.75 million. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The company's revenue for the quarter was down 24.8% compared to the same quarter last year. During the same period last year, the firm earned $1.25 earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 brokerages have issued 12 month price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.33 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Media coverage about ENTA stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Allakos (ALLK), Apellis Pharmaceuticals (APLS), Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT), Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO), Deciphera Pharmaceuticals (DCPH), Alkermes (ALKS), Amicus Therapeutics (FOLD) and ChemoCentryx (CCXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Wells Fargo & Co (WFC), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (8.83%), State Street Corp (4.19%), Renaissance Technologies LLC (3.69%), Acadian Asset Management LLC (1.74%), Goldman Sachs Group Inc. (1.68%) and Bank of New York Mellon Corp (0.95%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Marshall Wace North America L.P., AQR Capital Management LLC, Rafferty Asset Management LLC, UBS Group AG, Thrivent Financial for Lutherans and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Fairmount Funds Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Prudential Financial Inc., California Public Employees Retirement System, AJO LP and Aviva PLC. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $51.89.

Enanta Pharmaceuticals has a market capitalization of $1.03 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]